Table 4.

Difference in mean change in pain score between pregabalin and placebo groups in high placebo-response and low placebo-response studies stratified by age and sex

High placebo responsea					Difference	Low placebo responseb				Difference
	Pregabalin (n=709)		Placebo (n=353)			Pregabalin (n=2,290)		Placebo (n=1,161)
	n	Mean (SD)c	n	Mean (SD)c		n	Mean (SD)c	n	Mean (SD)c
DPN
Age, y
18–52	195	−2.59 (2.23)	98	−2.36 (2.31)	−0.23	319	−2.35 (2.21)	172	−1.80 (2.02)	−0.56
53–59	194	−2.74 (2.23)	92	−2.02 (2.06)	−0.71	292	−2.54 (2.42)	138	−1.39 (1.99)	−1.15
60–66	163	−2.98 (2.32)	94	−2.49 (2.00)	−0.49	347	−2.35 (2.20)	191	−1.28 (2.05)	−1.08
67–89	157	−2.21 (2.25)	69	−2.30 (2.51)	0.10	348	−2.37 (2.48)	184	−1.33 (2.20)	−1.04
Sex
Female	372	−2.76 (2.33)	190	−2.31 (2.07)	−0.45	516	−2.55 (2.37)	276	−1.54 (2.27)	−1.02
Male	337	−2.50 (2.19)	163	−2.28 (2.37)	−0.22	790	−2.30 (2.29)	409	−1.38 (1.94)	−0.92
PHNd
Age, y
18–52	–	–	–	–	–	57	−1.66 (2.24)	33	−2.19 (2.29)	0.53
53–59	–	–	–	–	–	85	−1.76 (2.36)	38	−1.25 (1.54)	−0.51
60–66	–	–	–	–	–	158	−2.56 (2.14)	79	−1.18 (2.06)	−1.38
67–89	–	–	–	–	–	679	−2.05 (2.18)	324	−0.83 (1.77)	−1.22
>89	–	–	–	–	–	5	−2.08 (4.35)	2	0.14 (0.20)	−2.22
Sex
Female	–	–	–	–	–	506	−2.35 (2.32)	231	−1.12 (1.92)	−1.23
Male	–	–	–	–	–	478	−1.81 (2.07)	245	−0.91 (1.82)	−0.89

Notes:

^aPooled placebo patients from DPN studies A0081030, A0081071, and A0081081 (DPN);

^bpooled placebo patients from DPN studies 1008-014,1008-029, 1008-040, 1008-131, 1008-149, 1008-155 (DPN), A0081060, and A0081163;

^cmean change (SD) from baseline in pain score at endpoint;

^dpooled placebo patients from PHN studies 1008-030, 1008-045, 1008-127, 1008-155 (PHN), 1008-196, A0081004, and A0081081 (PHN).

Abbreviations: DPN, diabetic peripheral neuropathy; PHN, postherpetic neuralgia; SD, standard deviation; y, years.